ABC Stock Recent News
ABC LATEST HEADLINES
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AmerisourceBergen (ABC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is how AmerisourceBergen (ABC) and Align Technology (ALGN) have performed compared to their sector so far this year.
AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
AmerisourceBergen (ABC) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $3.22 per share a year ago.
AmerisourceBergen Corp.'s stock ABC rose 0.8% premarket Tuesday, after the pharmaceutical services company's fiscal second-quarter earnings blew past estimates. The company had net income of $435.4 million, or $2.13 a share, for the quarter to March 31, down from $548.0 million, or $2.59 a share, in the year-earlier period.
AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
AmerisourceBergen's (ABC) new JV is expected to provide the independent community oncology network with additional resources and expertise to grow the platform and improve patient outcomes.
Asset management firm TPG Inc. TPG, +3.12% and pharmaceutical services company AmerisourceBergen Corp. ABC, -1.75% announced Thursday an agreement to buy oncology practices network OneOncology from private equity firm General Atlantic in a deal that values OneOncology at $2.1 billion. After the deal closes, which is expected to occur by the end of September 2023, TPG will own a majority of OneOncology, and AmerisourceBergen will pay $685 million in cash for a 35% stake.
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.